In the cardio-oncology population, drug interactions are of particular importance given the
complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies …

Doxorubicin-induced cardiotoxicity in childhood cancer survivors is a growing problem. The
population of patients at risk for cardiovascular disease is steadily increasing, as five-year …

Background: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene
and in combination with first-line therapy results in significantly improved survival outcomes …

Before the advent of the human epidermal growth factor receptor 2 (HER2)-targeted
monoclonal antibody trastuzumab, HER2-positive breast cancers were difficult to treat and …

Trastuzumab prolongs survival in women with HER2-positive breast cancer, but may
increase the risk of heart disease. The occurrence of severe cardiotoxicity, however, is not …

Trastuzumab prolongs progression-free and overall survival in patients with human
epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab …

Cancer cachexia is defined as a multifactorial syndrome of involuntary weight loss
characterized by an ongoing loss of skeletal muscle mass and progressive functional …

As the number of long-term breast cancer survivors has increased, the side effects of
adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the …

The introduction of multiple treatments for cancer, including chemotherapeutic agents and
radiation therapy, has significantly reduced cancer-related morbidity and mortality. However …

Over the past decades, there have been great advancements in the survival outcome of
patients with cancer. As a consequence, treatment regimens are being extended to patient …